Adenoviral interleukin-3 gene-radiation therapy for prostate cancer in mouse model.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 15145179.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The radiosensitizing effect of IL-3 gene therapy was evaluated on the syngeneic mouse prostate cancer model. An adenoviral vector was used to deliver the mIL-3 alpha gene into syngeneic murine prostate (TRAMP-C1) cancer cells growing in a subcutaneous site and the tumor response to irradiation was assessed. Ad-mIL-3 gene therapy showed no tumor growth delay without radiation. However, intratumoral Ad-mIL-3 injection with radiation therapy showed marked tumor growth delay that was significantly greater than that of radiation alone. The combined intratumoral Ad-mIL-3 gene therapy and radiation therapy is a valuable option for further clinical evaluation.
Medical subject headings
- Genetic Therapy
- Interleukin-3
- Prostatic Neoplasms